The Rise of CVRM Medicine: Managing Common Comorbidities as One — A Multispecialty Virtual Event

What you will learn

• The link between T2DM, CKD, and ASCVD
• Why early and effective intervention is important
• Guideline-driven treatment targets for CVRM
• How to develop a holistic management strategy

Faculty include Neha Pagidipati, Carel Le Roux, Lawrence Leiter, Tina Vilsbøll, Erika Jones, Hiddo Lambers Heerspink, Johannes Mann, Laura Meems, and Alice Cheng.

Programme

Part 1: T2DM and CVD: An evolving approach

• Residual risk and the need to shift from glucocentric management — Prof Tina Vilsbøll
• The progression of T2DM to ASCVD and the assessment of risk — Prof Tina Vilsbøll
• Management strategies and evidence-based impact on cardiovascular outcomes — Prof Lawrence Leiter

Part 2: CKD outcomes: Novel management strategies

• The role of CKD in CVRM disease — Prof Johannes Mann
• Established and emergent data for renal-protective CVRM treatment options — Prof Hiddo Lambers Heerspink
• Future clinical impact: Short discussion — Prof Erika Jones

Part 3: Holistic management of CVRM disease

• The interconnection of CVRM disease (T2DM, CKD, and ASCVD) — Dr Alice Cheng
• Optimal management strategies — Dr Laura Meems
• Turning insights into practice — Open discussion with faculty